Changing landscape of antiviral resistance management in chronic hepatitis B

Management of Antiviral Resistance in Chronic Hepatitis B

The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority o...

Antiviral resistance in hepatitis B

= Abstract = A high rate of viral turnover, combined with an error‐prone polymerase, results in an increased frequency of mutational events during hepatitis B virus (HBV) replication, resulting in a diverse population of progeny virus (quasispecies). Not suprising then, particular selection pressures, both from within (host immune clearance) or from outside (vaccines and antivirals) the host, r...

Frequency of YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines

 Abstract Background: Investigators were suspicious of tyrosine-methionine-aspartate-aspartate (YMDD) mutations occurred only in patients who were treated by lamivudine. However, YMDD mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines was reported in some studies. The aim of this study was to evaluate YMDD mutations in Ira...

[Antiviral therapy in chronic hepatitis B].

Treatment of chronic hepatitis B remains a clinical challenge. Long-term viral suppression is a major goal of antiviral therapy to improve the clinical outcome of the patients. Antiviral treatment of chronic hepatitis B relies currently on immune modulators such as interferon alpha and its pegylated form, and viral polymerase inhibitors. Because of the slow kinetics of viral clearance and the s...

[Antiviral combination therapy in chronic hepatitis B].